Shyam S. Chaurasia, MSc, PhD

Associate Professor of Ophthalmology & Visual Sciences; Associate Professor of Cell Biology, Neurobiology and Anatomy

Locations

EI 827

Contact Information

Education

Doctor of Philosophy (PhD), Life Sciences
Master of Science (MSc), Biochemistry
Bachelor of Science (BSc), Biochemistry

Biography

Dr. Shyam S. Chaurasia was born in Gwalior, also described as the “The Medieval Majestic Indian City with Music in its Soul.” He received his bachelor’s and master’s degrees in Science with Biochemistry as his major from the esteemed Nagpur University. He obtained a PhD degree from a globally ranked School of Life Sciences, Devi Ahilya University, Indore, India. He was awarded the prestigious Department of Biotechnology sponsored Postdoctoral Fellowship, and completed his Postdoctoral training in ophthalmology/neurosciences from Emory University, Atlanta, GA.

Dr. Chaurasia took his first faculty appointment in 2006 as a scientist at the Cole Eye Institute, Cleveland Clinic, Cleveland, OH. In 2009, he decided to move to Singapore and joined the Singapore Eye Research Institute, Singapore, and Institute of Molecular and Cellular Biology, A*STAR agency as an extramurally funded principal scientist/investigator. Later, he decided to return to the United States and took his first academic appointment as Assistant Professor on a tenure-track and successfully launched NIH/NEI-funded “Ocular Immunology & Angiogenesis Lab,” studying basic and translational research in vision sciences at the University of Missouri, Columbia, MO. In 2021, he joined as an associate professor in the Department of Ophthalmology and Visual Sciences/Eye Institute at MCW.

Honors and Awards

2020, Electron Microscopy Excellence Award, University of Missouri, Columbia, MO
2019, Electron Microscopy Excellence Award, University of Missouri, Columbia, MO
2018, Appeared on the local NBC News Channel in the Prime Time News, KOMU News Channel (NBC channel affiliate), Columbia, MO
2017, Electron Microscopy Excellence Award, University of Missouri, Columbia, MO
2011, Outstanding Young Research Award, Singapore Eye Research Institute, Singapore
2007, Association for Research in Vision and Ophthalmology (ARVO) Travel Award, ARVO, Rockville, MD
2006, Pineal Cell Biology Travel Award, Gordon Research Conferences, Buellton, CA
2005, X European Pineal and Biological Rhythm Society Congress Travel Award, European Pineal and Biological Rhythm Society Congress Travel Award, Frankfurt, Germany
2004, Pineal Cell Biology Travel Award, Gordon Research Conferences, Oxford, UK
2003, Mentor, BRAIN Summer Research Program, Center for Behavioral Neuroscience, Emory University, Atlanta, GA

Research Interests

Dr. Chaurasia’s Ocular Immunology and Angiogenesis Lab is funded by NIH/NEI and focuses on the Molecular Basis of Eye Diseases for the development of a highly innovative basic and translational multidisciplinary research program in the identification and validation of novel biomarkers and targets, and evaluate potential VEGF-independent Next-Generation Precision therapeutics/Medicine to treat Ocular Fibrotic and Angiogenic Diseases (OFADs). Dr. Chaurasia has substantial experience in basic and translational vision sciences, as evident from published more than 100 peer-reviewed research papers and 150+ scientific abstracts and presentations at the national and international level.

Research Experience

Diabetic Retinopathy & Diabetic Macular Edema
Age-related Macular Degeneration
Retinopathy of Prematurity
Fibrotic Eye Diseases
Nanomedicine & Wound healing therapeutics in the Eye
Next-Gen Tools in Precision Medicine for Retinal Degenerative Diseases
Countermeasures Against Chemical Threats (CounterACT)

ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells.

(Lim RR, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W, Kim JE, Barathi VA, Ghosh A, Chaurasia SS.) FASEB J. 2024 Mar 15;38(5):e23512 PMID: 38430220 SCOPUS ID: 2-s2.0-85186559682 03/02/2024
Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo.

(Mohan RR, Gupta S, Kumar R, Sinha NR, Landreneau J, Sinha PR, Tandon A, Chaurasia SS, Hesemann NP.) Ocul Surf. 2024 Jan 06;32:13-25 PMID: 38191093 SCOPUS ID: 2-s2.0-85182147133 01/09/2024
Hyperglycemia-induced miR182-5p drives glycolytic and angiogenic response in Proliferative Diabetic Retinopathy and RPE cells via depleting FoxO1.

(Shanbagh S, Gadde SG, Shetty R, Heymans S, Abilash VG, Chaurasia SS, Ghosh A.) Exp Eye Res. 2024 Jan;238:109713 PMID: 37952722 SCOPUS ID: 2-s2.0-85178139041 11/13/2023
Depleted hexokinase1 and lack of AMPKα activation favor OXPHOS-dependent energetics in retinoblastoma tumors.

(Babu VS, Mallipatna A, Dudeja G, Shetty R, Nair AP, Tun SBB, Ho CEH, Chaurasia SS, Bhattacharya SS, Verma NK, Lakshminarayanan R, Guha N, Heymans S, Barathi VA, Ghosh A.) Transl Res. 2023 Nov;261:41-56 PMID: 37419277 SCOPUS ID: 2-s2.0-85167435325 07/08/2023
New Insights into RPE-Photoreceptor Complex Ultrastructure using Focused Ion Beam-Scanning Election Microscopy (FIB-SEM).

(Low SWY, Lim RR, Grant DG, Patterson S, Chaurasia SS.) Res Sq. 2023 Aug 07 PMID: 37609321 PMCID: PMC10441459 08/23/2023
Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.

(Mahaling B, Low SWY, Ch S, Addi UR, Ahmad B, Connor TB, Mohan RR, Biswas S, Chaurasia SS.) Pharmaceutics. 2023 Jul 22;15(7) PMID: 37514191 PMCID: PMC10383092 SCOPUS ID: 2-s2.0-85166338712 07/29/2023
Mustard Gas Exposure Actuates SMAD2/3 Signaling to Promote Myofibroblast Generation in the Cornea.

(Sinha NR, Tripathi R, Balne PK, Suleiman L, Simkins K, Chaurasia SS, Mohan RR.) Cells. 2023 Jun 02;12(11) PMID: 37296653 PMCID: PMC10252656 SCOPUS ID: 2-s2.0-85163141524 06/10/2023
Distinct gene expression profiles underlie morphological and etiological differences in pediatric cataracts.

(Shanbagh S, Matalia J, Kannan R, Shetty R, Panmand P, Muthu SO, Chaurasia SS, Deshpande V, Bhattacharya SS, Gopalakrishnan AV, Ghosh A.) Indian J Ophthalmol. 2023 May;71(5):2143-2151 PMID: 37203095 PMCID: PMC10391435 SCOPUS ID: 2-s2.0-85159765396 05/19/2023
Mustard gas exposure instigates retinal Müller cell gliosis.

(Mahaling B, Sinha NR, Sokupa S, Addi UR, Mohan RR, Chaurasia SS.) Exp Eye Res. 2023 May;230:109461 PMID: 37023936 PMCID: PMC10157651 SCOPUS ID: 2-s2.0-85151717505 04/07/2023
Selective Induction of Intrinsic Apoptosis in Retinoblastoma Cells by Novel Cationic Antimicrobial Dodecapeptides.

(Suresh Babu V, Kizhakeyil A, Dudeja G, Chaurasia SS, Barathi VA, Heymans S, Verma NK, Lakshminarayanan R, Ghosh A.) Pharmaceutics. 2022 Nov 18;14(11) PMID: 36432697 PMCID: PMC9694048 11/27/2022
Time-dependent in situ structural and cellular aberrations in rabbit cornea in vivo after mustard gas exposure.

(Sinha NR, Tripathi R, Balne PK, Green SL, Sinha PR, Bunyak F, Giuliano EA, Chaurasia SS, Mohan RR.) Exp Eye Res. 2022 Nov;224:109247 PMID: 36113569 SCOPUS ID: 2-s2.0-85138805719 09/17/2022
Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo.

(Gupta S, Fink MK, Kempuraj D, Sinha NR, Martin LM, Keele LM, Sinha PR, Giuliano EA, Hesemann NP, Raikwar SP, Chaurasia SS, Mohan RR.) Mol Ther. 2022 Oct 05;30(10):3334 PMID: 36029769 PMCID: PMC9552807 SCOPUS ID: 2-s2.0-85138993905 08/28/2022